WHO Advises Not To Use 2 Marion Biotech Cough Syrups In Uzbekistan

New Delhi : The World Health Organization on Wednesday said that two cough syrups made by India’s Marion Biotech should not be used for children, after the products were linked to 19 deaths in Uzbekistan.

Analysis by Uzbekistan’s health ministry showed the syrups, Ambronol and DOK-1 Max, contained a toxic substance, ethylene glycol. The syrups were administered in doses higher than the standard for children, either by their parents, who mistook it for an anti-cold remedy, or on the advice of pharmacists, according to the analysis.

So far, Marion has not provided guarantees to WHO on the safety and quality of these products, the agency said. Shortly after the series of deaths were reported in Uzbekistan, India’s health ministry suspended production at the company. According to a recent report, India’s Uttar Pradesh state has suspended Marion’s production license.

Marion did not immediately respond to a Reuters request for comment. Last week, the Uzbek state security service arrested four people in an investigation into the cough-syrup related deaths of 19 children.

The Uzbekistan case follows deaths of at least 70 children in Gambia that a parliamentary committee had linked to cough and cold syrups manufactured by New Delhi-based Maiden Pharmaceuticals. The company denied any wrongdoing and Indian government inspectors found no contamination in test samples.

Related Posts

Aurobindo Pharma Rs 800 Cr Buyback Opens Apr 23

New Delhi:  Aurobindo Pharma Ltd on Tuesday said it has set April 23 as the opening date for its Rs 800 crore buyback offer. The closing date for the buyback…

Boehringer Ingelheim launches AI centre for pharma research in London

Bengaluru: German drugmaker Boehringer Ingelheim is launching a ​centre for artificial ​intelligence and machine learning in London, it said ​on Monday, as it seeks to expand its AI capabilities in…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

Aurobindo Pharma Rs 800 Cr Buyback Opens Apr 23

Aurobindo Pharma Rs 800 Cr Buyback Opens Apr 23

Boehringer Ingelheim launches AI centre for pharma research in London

Boehringer Ingelheim launches AI centre for pharma research in London

Pharma exports rose 2% to over $31 billion in FY26 despite sharp decline in March

Pharma exports rose 2% to over $31 billion in FY26 despite sharp decline in March

Centre Urges States To Enforce Clinical Establishments Act & Standardise Hospital Rates

Centre Urges States To Enforce Clinical Establishments Act & Standardise Hospital Rates

Piramal, Ajinomoto team on ADC development and manufacturing

Piramal, Ajinomoto team on ADC development and manufacturing

Aurobindo Pharma Gets USFDA Nod for Glycerol Liquid

Aurobindo Pharma Gets USFDA Nod for Glycerol Liquid